TacticScaleWhat Perrigo Does & How It Makes Money (PRGO)
Updated October 2026 · reflects Perrigo's latest reported financials
Store-brand and branded over-the-counter self-care products maker. It earns revenue by selling branded and retailer-focused OTC self-care products in bulk to retailers, wholesalers, and pharmacies, plus fees from contract manufacturing services.
How Perrigo makes money
It earns revenue by selling branded and retailer-focused OTC self-care products in bulk to retailers, wholesalers, and pharmacies, plus fees from contract manufacturing services.
What Perrigo does
Perrigo Company plc is a Dublin-headquartered consumer self-care company with roots dating to 1887. It reports through two segments, Consumer Self-Care Americas and Consumer Self-Care International. Its range covers upper respiratory, nutrition (infant formula and oral electrolyte drinks), digestive health, pain and sleep aids, oral care, skin care, women's health, smoking cessation, and vitamins and supplements. Brands include Compeed, Mederma, Nasonex, Prevacid24HR, Opill, NiQuitin, ellaOne, Solpadeine, Coldrex, Physiomer, Plackers, and Dr. Fresh. Perrigo reaches consumers through drug, grocery, and mass-merchandise retailers, e-commerce, wholesalers, pharmacies, and para-pharmacies, and it also does contract manufacturing for other companies.
Products & services
- Compeed
- Mederma
- Nasonex
- Opill
- Good Start infant formula
- Plackers
What is Perrigo worth?
On an owner-earnings DCF, Perrigo's most-likely value is about $23 versus a recent price near $15 (54% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$17) with a margin of safety — so the honest verdict here is “Deeply discounted.” Fair value earns its keep only at the extremes, not in the wide middle.
On the financials alone, $15 is below even the no-growth floor ($17); the market's discount — expectations and sentiment beyond the numbers — is pricing in ≈ -1.8%/yr. A bargain only if that pessimism is overdone.
⚠ High leverage — net debt is 12.2× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Prestige Consumer Healthcare (PBH) · The Procter & Gamble (PG) · Pfizer (PFE) · Colgate-Palmolive (CL)